- Conditions
- Primary Open Angle Glaucoma or Ocular Hypertension
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 40
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 5,498
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastrointestinal Discomfort, Bloating
- Interventions
- Active: Multi-strain probiotic dietary supplement, Placebo: Placebo
- Dietary Supplement
- Lead sponsor
- Daily Nouri
- Industry
- Eligibility
- 25 Years to 45 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Frontotemporal Lobar Degeneration
- Interventions
- Tolcapone, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity
- Interventions
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Psoriatic Arthritis
- Interventions
- Placebo, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 72
- States / cities
- Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more
- Conditions
- Palmoplantar Pustulosis
- Interventions
- Imsidolimab, Placebo
- Biological · Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Encino, California + 15 more
- Conditions
- Cardiovascular Disease
- Interventions
- Dalcetrapib, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 936 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 41
- States / cities
- Los Angeles, California • Torrance, California • Boulder, Colorado + 36 more
- Conditions
- Opioid-use Disorder, Heroin Abuse, Craving, Transcranial Magnetic Stimulation
- Interventions
- Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- San Diego, La Jolla, California • Gainesville, Florida
- Conditions
- Hepatitis C, Chronic
- Interventions
- Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 85
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Alzheimer Disease
- Interventions
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos
- Drug
- Lead sponsor
- T3D Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
- Interventions
- Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
- Combination Product · Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 45
- States / cities
- Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
- Conditions
- Actinic Keratosis
- Interventions
- LEO 43204, Placebo
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Snellville, Georgia
- Conditions
- Type II Diabetes Mellitus
- Interventions
- CX11, Placebo
- Drug · Other
- Lead sponsor
- Corxel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 28 more
- Conditions
- Parkinson Disease
- Interventions
- KM-819, Placebo
- Drug
- Lead sponsor
- FAScinate Therapeutics Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Glendale, California • San Diego, California • Royal Oak, Michigan
- Conditions
- Diabetic Nephropathy
- Interventions
- Nidufexor, Placebo, Standard of Care (SoC)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
- Conditions
- Hyperlipidemia
- Interventions
- Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
- Conditions
- Anaemia
- Interventions
- GSK1278863, Placebo, rhEPO
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 17
- States / cities
- Azusa, California • Los Angeles, California • San Dimas, California + 13 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- levocetirizine dihydrochloride, placebo
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more
- Conditions
- Molluscum Contagiosum
- Interventions
- SB206 12%, Placebo
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more
- Conditions
- Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
- Interventions
- mazindol extended release, Placebo
- Drug
- Lead sponsor
- NLS Pharmaceutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more
- Conditions
- Age Related Macular Degeneration (ARMD)
- Interventions
- Elamipretide, Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more